TRANSMITTAL  
FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

10

Application Number

10/705,282

Filing Date

11/10/2003

First Named Inventor

Chackalamannil

Art Unit

1625

Examiner Name

To Be Assigned

Attorney Docket Number

CV01185K1X

## ENCLOSURES

(Check all that apply)



Fee Transmittal Form



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Certified Copy of Priority Document(s)

Reply to Missing Parts/  
Incomplete ApplicationReply to Missing Parts  
under 37 CFR 1.52 or 1.53

Drawing(s)



Licensing-related Papers



Petition

Petition to Convert to a  
Provisional ApplicationPower of Attorney, Revocation  
Change of Correspondence Address

Terminal Disclaimer



Request for Refund



CD, Number of CD(s) \_\_\_\_\_

☐ Landscape Table on CID

After Allowance Communication to TC

Appeal Communication to Board  
of Appeals and InterferencesAppeal Communication to TC  
(Appeal Notice, Brief, Reply Brief)

Proprietary Information



Status Letter

Other Enclosure(s) (please identify  
below):PTO Form 1449 (3 pages); References  
(53 documents); Post Card

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

Schering-Plough Corporation

Signature

Printed name

Gerard E. Reinhardt

Date

June 08, 2005

Reg. No.

43,041

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:


Signature

Typed or printed name

Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED I TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): **Chackalamannil, S., et.al.**

Application No.: **10/705,282**

Filed: **November 10, 2003**

For: **Methods of Use of  
Thrombin Receptor Antagonists**

Group Art Unit: **1625**

Examiner: **To Be Assigned**

Attorney Docket No. : **CV01185K1X**

X

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

(a) Pursuant to the duty of disclosure under 37 C.F.R. § 1.56, it is requested that the documents listed on the accompanying Form PTO-1449 be considered and made of record in the above-identified patent application. Other than cited U.S. patents and published patent applications, copy(ies) of these documents ☒ are enclosed ☐ were filed in related U.S. Application No(s) **10/705,282** filed **November 10, 2003**, respectively. Since the Examiner is believed to have ready access to the cited U.S. patents and published patent applications, copies of these documents are not herewith transmitted, but will be provided upon request.

(b) No fee is believed to be due because:

- ☐ This Information Disclosure Statement is being submitted concurrently with the filing of the above-identified application; **or**
- ☐ This Information Disclosure Statement is being submitted within three (3) months of the filing date of the above-identified application; **or**
- ☐ This Information Disclosure Statement is being submitted concurrently with a Request for Continued Examination (RCE); **or**
- ☐ This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits.

(c) ☒ This Information Disclosure Statement is being submitted before the mailing date of any final action, notice of allowance, or an action that otherwise closes prosecution; and:

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; **or**

06/09/2005 FMTEK11 00000087 190365 10705282

01 FC:1806 180.00 DA

☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; **or**

☒ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

(d) ☐ This Information Disclosure Statement is being submitted on or before the payment of the issue fee; and:


☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; **or**

☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; **and**

☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0365. A DUPLICATE COPY OF THIS SHEET IS ENCLOSED.

Dated: **June 8, 2005**  
**Schering-Plough Corporation**  
Patent Department, K-6-1, 1990  
2000 Galloping Hill Road  
Kenilworth, NJ 07033-0530  
Facsimile No.: (908) 298-5388


Respectfully submitted,  
  
By: \_\_\_\_\_  
Gerard E. Reinhardt  
Reg. No.: 43,041  
**Attorney of Record**  
Telephone No.: (908) 298-2960

Express Mail Label: EV 533188599 US

PTO/SB/17 (12-04v2)

Approved for use through 07/31/2006. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

Effective on 1210812004.  
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

# FEE TRANSMITTAL

## For FY 2005

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180.00)

## Complete if Known

|                      |                |
|----------------------|----------------|
| Application Number   | 10/705,282     |
| Filing Date          | 11/10/2003     |
| First Named Inventor | Chackalamannil |
| Examiner Name        | To Be Assigned |
| Art Unit             | 1625           |
| Attorney Docket No.  | CV01185K1X     |

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): \_\_\_\_\_

☒ Deposit Account Deposit Account Number: 19-0365 Deposit Account Name: Schering-Plough Corporation.

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

## FEE CALCULATION

## 1. BASIC FILING, SEARCH, AND EXAMINATION FEES

| Application Typ | FILING FEES<br>Fee (\$) | SEARCH FEES<br>Fee (\$) | EXAMINATION FEES<br>Fee (\$) | Fees Paid (\$) |
|-----------------|-------------------------|-------------------------|------------------------------|----------------|
| utility         | 300                     | 500                     | 200                          |                |
| Design          | 200                     | 100                     | 130                          |                |
| Plant           | 200                     | 300                     | 160                          |                |
| Reissue         | 300                     | 500                     | 600                          |                |
| Provisional     | 200                     | 0                       | 0                            |                |

## 2. EXCESS CLAIM FEES

| Fee Description   | Fee (\$) |
|---|----------|
| Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent            | 50       |
| Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent | 200      |
| Multiple dependent claims   | 360      |

| Total Claims  | Extra Claims | Fee (\$) | Fee Paid (\$) | Multiple Dependent Claims | Fee (\$) | Fee Paid (\$) |
|---|--------------|----------|---------------|---------------------------|----------|---------------|
| - 20 or HP =  | x            |          |               |                           |          |               |
| HP = highest number of total claims paid for, if greater than 20      |              |          |               |                           |          |               |
| Indep. Claims   | Extra Claims | Fee (\$) | Fee Paid (\$) |                           |          |               |
| - 3 or HP =   | x            |          |               |                           |          |               |
| HP = highest number of independent claims paid for, if greater than 3 |              |          |               |                           |          |               |

## 3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41 (a)(1)(G) and 37 CFR 1.16(s).

| Total Sheets | Extra Sheets | Number of each additional 50 or fraction thereof | Fee (\$) | Fee Paid (\$) |
|--------------|--------------|--|----------|---------------|
| - 100=       | /50=         | (round up to a whole number) x                   |          |               |

## 4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): Information Disclosure Statement

180.00

## SUBMITTED BY

|                   |                            |   |                        |
|-------------------|----------------------------|---|------------------------|
| Signature         | <i>Gerard E. Reinhardt</i> | Registration No.<br>(Attorney/Agent) 43,041 | Telephone 908-298-2960 |
| Name (Print/Type) | Gerard E. Reinhardt        | Date  | June 08, 2005          |

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

|   |    |  |          |                                  |       |                           |                               |
|---|----|--|----------|----------------------------------|-------|---------------------------|-------------------------------|
| FORM PTO-101 (Rev. 11-2000)   |    | U.S. DEPARTMENT OF COMMERCE<br>PATENT AND TRADEMARK OFFICE   |          | ATTY. DOCKET NO.:<br>CV01185K1X  |       | SERIAL NO.:<br>10/705,282 |                               |
| INFORMATION DISCLOSURE STATEMENT<br>BY APPLICANT<br><br>(Use several sheets if necessary) |    |  |          | APPLICANT:<br>Chackalamannil, S. |       |                           |                               |
|   |    |  |          | FILING DATE:<br>11/10/2003       |       | GROUP:<br>1625            |                               |
| U.S. PATENT DOCUMENTS   |    |  |          |                                  |       |                           |                               |
| EXAMINER<br>INITIAL   |    | DOCUMENT<br>NUMBER   | DATE     | NAME                             | CLASS | SUB-<br>CLASS             | FILING DATE IF<br>APPROPRIATE |
|   | AA | 6,063,847  | 05/16/00 |                                  |       |                           |                               |
|   | AB | 6,326,380 B1   | 12/04/01 |                                  |       |                           |                               |
|   | AC | 6,645,987  | 11/11/03 |                                  |       |                           |                               |
|   | AD | 6,894,065  | 05/17/05 |                                  |       |                           |                               |
|   | AE | 03/0216437   | 11/20/03 |                                  |       |                           |                               |
|   |    |  |          |                                  |       |                           |                               |
|   |    |  |          |                                  |       |                           |                               |
| FOREIGN PATENT DOCUMENTS  |    |  |          |                                  |       |                           |                               |
|   |    | DOCUMENT<br>NUMBER   | DATE     | COUNTRY                          | CLASS | SUB-<br>CLASS             | TRANSLATION<br>YES NO         |
|   | AF | WO/9926943 A   | 06/03/99 |                                  |       |                           |                               |
|   | AG | WO/0196330 A   | 12/20/01 |                                  |       |                           |                               |
|   | AH | Invitation to pay<br>additional fees   | 06/05/05 |                                  |       |                           |                               |
|   | AI |  |          |                                  |       |                           |                               |
|   | AJ |  |          |                                  |       |                           |                               |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)                    |    |  |          |                                  |       |                           |                               |
|   | AK | Ahn, Ho-Sam, et.al. "Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases", CURRENT PHARMACEUTICAL DESIGN, Vol. 9 (28) pp. 2349 – 2365, (2003).                                   |          |                                  |       |                           |                               |
|   | AL | Asanuma, Kunihiro, et.al. "Thrombin Inhibitor, Argatroban, Prevents Tumor Cell Migration and Bone Metastasis", ONCOLOGY, Vol. 67(2), pp. 166 – 173, (2004).  |          |                                  |       |                           |                               |
|   | AM | Asokanathan, Nithianathan, et.al. "Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells", JOURNAL OF IMMUNOLOGY, Vol. 168 (7), pp. 3577 – 3585, (2002). |          |                                  |       |                           |                               |
|   | AN | Barrios, Victor, et.al. "Proteinase-activated receptor-2 mediates hyperresponsiveness in isolated guinea pig bronchi.", BIOCHEMICAL PHARMACOLOGY, Vol. 66 (3), pp. 519-525, (2003).  |          |                                  |       |                           |                               |
|   | AO | Buresi, M.C., et.al. "Protease-activated receptor-1 stimulates Ca2+-dependent Cl- secretion in human intestinal epithelial cells", AMERICAN JOURNAL OF PHYSIOLOGY- GASTRO INTEST LIVER PHYSIOL Vol. 281 (2, Pt. 1), G323-G332, (2001)                              |          |                                  |       |                           |                               |
|   | AP | Copple, Bryan, L., et. al. "Thrombin and protease-activated receptor-1 agonists promote lipopolysaccharide-induced hepatocellular injury in perfused livers", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, Vol. 305 (2), pp. 417 – 425, (2003)           |          |                                  |       |                           |                               |
|   | AQ | Chambers, R.C.,et.al. "Coagulation cascade proteases and tissue fibrosis", BIOCHEMICAL SOCIETY TRANSACTIONS, Vol. 30 (2), pp. 194 – 200, (2002).   |          |                                  |       |                           |                               |
|   | AR | Chambers, R.C., "Proteinase-activated receptors and the pathophysiology of pulmonary fibrosis", DRUG DEVELOPMENT RESEARCH, Vol. 60(1), pp. 29-35, (2003).  |          |                                  |       |                           |                               |
|   | AS | Coughlin, S., et.al. "PARTicipation in inflammation. JOURNAL OF CLINICAL INVESTIGATION, 111(1), pp. 25-27, (2003).   |          |                                  |       |                           |                               |
|   | AT | D'Andrea, M. et.al., "Expression of protease-activated receptor-1, -2, -3, and -4 in control and experimentally inflamed mouse bladder", AMERICAN JOURNAL OF PATHOLOGY, Vol. 162(3), pp. 907-923, (2003).  |          |                                  |       |                           |                               |
|   | AU | Darmoul, Dalila, et.al., "Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation", MOLECULAR CANCER RESEARCH, Vol. 2(9), pp. 514-522, (2004).                       |          |                                  |       |                           |                               |
|   | AV | Derian, Claudia, et.al., "Therapeutic potential of protease-activated receptor-1 antagonists. Expert Opinion on Investigational Drugs Vol. 12(2), 209-221, (2003).   |          |                                  |       |                           |                               |
|   | AW | Even-Ram, Sharona, et. al., "The pattern of expression of protease-activated receptors (PARs) during early trophoblast development", JOURNAL OF PATHOLOGY, Vol. 200(1), pp. 47-52, (2003).   |          |                                  |       |                           |                               |

|    |  |
|----|--|
| AX | Even-Ram, Sharona, et. al., "Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the $\alpha\beta 5$ integrin", JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 276(14), pp.10952-10962, (2001).  |
| AY | Feistritzer, Clemens, et.al., "Thrombin Affects Eosinophil Migration via Protease-Activated Receptor-1", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, Vol. 135 (1), 12-16, (2004).  |
| AZ | Ferroni, P., et.al., "Platelet activation in type 2 diabetes mellitus" JOURNAL OF THROMBOSIS AND HAEMOSTASIS Vol. 2(8), pp. 1282-1291, (2004).   |
| BA | Flynn, A.N., et.al., "Proteinase-activated receptor 1 (PAR-1) and cell apoptosis" APOPTOSIS, Vol. 9(6), pp. 729-737, (2004).   |
| BB | Fiorucci, Stefano, et.al., "PAR1 antagonism protects against experimental liver fibrosis.Role of proteinase receptors in stellate cell activation" HEPATOLOGY, Vol. 39(2), pp. 365-375 (2004).   |
| BC | Fortini, Mark, "PAR-1 for the course of neurodegeneration" CELL Vol. 116(5), pp. 631-632, (2004).  |
| BD | Gabazza, Esteban C, "Progress in the understanding of protease-activated receptors", INTERNATIONAL JOURNAL OF HEMATOLOGY, Vol. 79(2), pp.117-122, (2004).  |
| BE | Gaca, Marianna, et.al. "Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors" JOURNAL OF HEPATOLOGY, Vol. 36(3), pp. 362-369, (2002).  |
| BF | Hauck, R.W, et.al. "Alpha-Thrombin stimulates contraction of human bronchial rings by activation of protease-activated receptors" AMERICAN JOURNAL OF PHYSIOLOGY, Vol. 277(1, Pt. 1), L22-L29, (1999).   |
| BG | Howell, D.C.,et.al. "Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis" AMERICAN JOURNAL OF PATHOLOGY Vol. 159(4), pp. 1383-95, (2001).  |
| BH | Jin, Enjing, et.al. "Protease-activated receptor (PAR)-1 and PAR-2 participate in the cell growth of alveolar capillary endothelium in primary lung adenocarcinomas". CANCER Vol. 97(3), pp. 703-713. (2003).  |
| BI | Jurasz, Paul, et.al. "Platelet-cancer interactions: Mechanisms and pharmacology of tumour cell-induced platelet aggregation" BRITISH JOURNAL OF PHARMACOLOGY, Vol. 143(7), pp. 819-826, (2004).  |
| BJ | Kawabata, Atsufumi "Gastrointestinal functions of proteinase-activated receptors" LIFE SCIENCES, Vol. 74(2-3), pp. 247-254, (2003).  |
| BK | Kuroda, Ryotaro, et.al. "Pain information pathways from the periphery to the cerebral cortex" Yakugaku Zasshi, Vol. 123(7), pp. 533-546, (2003).   |
| BL | Lan, Rommel, et.al. "Altered expression and in vivo lung function of protease-activated receptors during influenza A virus infection in mice" AMERICAN JOURNAL OF PHYSIOLOGY: LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, Vol. 286(2), L388-98, (2004).                                      |
| BM | Liu, Jian, et.al. "Expression of functional protease-activated receptor 1 in human prostate cancer cell lines" UROLOGICAL RESEARCH Vol. 31(3), pp. 163-168, (2003).  |
| BN | Liu, Y., et.al. "Expression of protease-activated receptor 1 in oral squamous cell carcinoma" CANCER LETTERS Vol. 169(2), pp. 173-180, (2001).   |
| BO | Moffatt, James, et.al. "Effects of inhaled thrombin receptor agonists in mice" British Journal of Pharmacology Vol. 143(2), pp. 269-275 (2004).  |
| BP | Miyata, Satoshi, et.al. "Trypsin stimulates integrin $\alpha 5 \beta 1$ -dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2" JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 275(7), pp. 4592-4598, (2000). |
| BQ | Nierodzik, M. L., et.al. "Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis" BLOOD Vol. 92(10), pp. 3694-700, (1998).  |
| BR | Rattenholl, Anke, et.al. "Role of proteinase-activated receptors in cutaneous biology and disease" DRUG DEVELOPMENT RESEARCH Vol. 59(4), pp. 408-416, (2003).  |
| BS | Reed, Charles, et. al. "The role of protease activation of inflammation in allergic respiratory diseases" JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, Vol. 114(5), 997-1008, (2004).   |
| BT | Reiter, Rosemarie, et.al. "Regulation of protease-activated receptor I (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans" THROMBOSIS AND HAEMOSTASIS Vol. 90(5), 898-903 (2003).                              |
| BU | Robey, R.B., et.al. "Thrombin is a novel regulator of hexokinase activity in mesangial cells" KIDNEY INTERNATIONAL Vol. 57(6), pp. 2308-18. Journal code: 0323470, (2000)  |
| BV | Roche, Nicholas, et. al. "Effect of acute and chronic inflammatory stimuli on expression of protease-activated receptors 1 and 2 alveolar macrophages. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY Vol. 111(2), pp. 367-373, (2003).  |

|  |    |   |
|--|----|---|
|  | BW | Rohatgi, Tanuja, et.al. "Protease-Activated Receptors in Neuronal Development, Neurodegeneration, and Neuroprotection: Thrombin as Signaling Molecule in the Brain", THE NEUROSCIENTIST, Vol 10 (6), pp. 501 – 512, (2004).   |
|  | BX | Ruf, W., et.al. "Specificity of coagulation factor signaling" JOURNAL OF THROMBOSIS AND HAEMOSTASIS Vol. 1(7), pp. 1495-1503, (2003).   |
|  | BY | Sekiguchi, Fumiko, et.al. "Protease-activated receptors (PARs) as therapeutic targets: Development of agonists/antagonists and modulation of gastrointestinal functions" DRUG DESIGN REVIEWS – Online Vol. 1(4), pp. 287-296, (2004).   |
|  | BZ | Shi, Xiaoli, et.al. "Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis" MOLECULAR CANCER RESEARCH Vol. 2(7), 395-402, (2004).   |
|  | CA | Shimizu, Tadamichi, et.al. "Macrophage Migration Inhibitory Factor Is Induced by Thrombin and Factor Xa in Endothelial Cells" JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 279(14), pp. 13729-13737, (2004).  |
|  | CB | Thamboo, T. P., et. al. "Hep Par 1 expression in carcinoma of the cervix: Implications for diagnosis and prognosis" JOURNAL OF CLINICAL PATHOLOGY Vol. 57(1), 48-53, (2004).  |
|  | CC | Tran, Thai, et. al. "Protease-activated receptor (PAR)-independent growth and pro-inflammatory actions of thrombin on human cultured airway smooth muscle" British Journal of Pharmacology 138(5), 865-875, (2003).   |
|  | CD | Vergnolle, Nathalie, et.al. "A role for proteinase-activated receptor-1 in inflammatory bowel diseases", JOURNAL OF CLINICAL INVESTIGATION Vol. 114(10), 1444-56 (2004).  |
|  | CE | Villari, D., et.al. "Hep Par 1 in gastric and bowel carcinomas: an immunohistochemical study" PATHOLOGY Vol. 34(5), pp. 423-426, (2002).  |
|  | CF | Wang, Junru, et.al. "Deficiency of microvascular thrombomodulin and up-regulation of protease-activated receptor-1 in irradiated rat intestine: Possible link between endothelial dysfunction and chronic radiation fibrosis" AMERICAN JOURNAL OF PATHOLOGY Vol. 160(6), 2063-2072, (2002). |
|  | CG | Yin, Yong-Jun, et.al. "Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation. FASEB JOURNAL Vol. 17(2), pp. 163-174, (2003).  |
|  | CH | Yuan Ta Chun, et.al. "Protease-activated receptor 1: a role in prostate cancer metastasis" CLINICAL PROSTATE CANCER Vol. 3(3), pp. 189-91, (2004).  |
|  | CI | Zhang, Xin, et.al. "Correlation of Protease-Activated Receptor-1 With Differentiation Markers in Squamous Cell Carcinoma of the Head and Neck and Its Implication in Lymph Node Metastasis. CLINICAL CANCER RESEARCH Vol. 10(24), pp. 8451-8459, (2004).                                    |
|  | CJ |   |
|  | CK |   |
|  | CL |   |
|  | CM |   |
|  | CN |   |
| EXAMINER   |    | DATE CONSIDERED   |
| <p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> |    |   |